Core Viewpoint - The article emphasizes that the significant increase in net profit (143.7%) compared to revenue growth (35.1%) indicates a shift in the company's growth strategy from "product-driven growth" to "scale-driven profitability" [3][4][26]. Financial Performance - The company reported a revenue of 1.057 billion RMB, a year-on-year increase of 35.1%, and a net profit of 244.37 million RMB, a year-on-year increase of 143.7% [2][7]. - The gross profit margin remained high at 72.1%, indicating stable product structure and cost control capabilities [7][23]. - The significant profit growth suggests that fixed costs are being rapidly diluted, showcasing the emergence of scale effects [8][30]. Growth Drivers - Revenue growth is driven by two main lines: simultaneous acceleration in both neurovascular and peripheral vascular interventions [10][12]. - The neurovascular intervention segment generated 676 million RMB (+28.0%), while the peripheral vascular intervention segment saw a growth of 379 million RMB (+50.3%) [12]. - The company is transitioning from reliance on single product cycles to a more diversified product pipeline, with 79 products in total and 61 already launched [17][18]. International Expansion - The company's overseas revenue reached 48.65 million RMB, marking a 115.5% increase, with a compound annual growth rate of 84% over the past four years [19][20]. - This growth indicates that the company has completed the initial phase of internationalization, although the overseas business is still in the investment phase and not yet a profit center [21][30]. Profitability Amid Price Pressure - The company maintains a high gross margin despite price pressures from centralized procurement due to three factors: product differentiation, scale effects, and optimized product structure [23][24][25]. - High-value products have increased in proportion, helping to offset some pricing pressures [25]. Future Outlook - The focus moving forward should be on whether profit elasticity can be sustained and if international operations can transition from expansion to contribution [30]. - The company has successfully navigated one of the most challenging phases for medical device companies, moving from having products to effectively selling them [31][32].